SLC5A2 and type 2 diabetes mellitus: Chunk 4 (IDFc Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care—201728): “Many guidelines consider basal insulin as the best option when the HbA1c target has not been achieved...Since the completion of the review of guidelines for this document, new cardiovascular safety trials have been reported with two SGLT2 inhibitors (empagliflozin and canagliflozin) and with two long.”